UBS Group’s Acadia Pharmaceuticals ACAD Stock Holding History

UBS Group’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-29,200	Closed	-$1.42M	–	7931
2020 Q2	$1.42M	Buy	+29,200	New	+$1.4M	﹤0.01%	3200
2020 Q1	–	Sell	-47,000	Closed	-$2.01M	–	7906
2019 Q4	$2.01M	Buy	+47,000	New	+$2.04M	﹤0.01%	3541
2016 Q1	–	Sell	-2,900	Closed	-$103K	–	7574
2015 Q4	$103K	Hold	2,900	–	–	﹤0.01%	5177
2015 Q3	$96K	Sell	2,900 -400	-12%	-$16.6K	﹤0.01%	5267
2015 Q2	$138K	Sell	3,300 -30,200	-90%	-$1.17M	﹤0.01%	5163
2015 Q1	$1.09M	Sell	33,500 -40,300	-55%	-$1.39M	﹤0.01%	3491
2014 Q4	$2.34M	Buy	+73,800	New	+$2.09M	﹤0.01%	2752

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

UBS Group's ACAD Position: Q1 2026 in Review

UBS Group reduced its Acadia Pharmaceuticals (ACAD) stake by 42% in Q1 2026, selling an estimated $7.67M and leaving 448,549 shares worth $9.98M. The position accounts for ﹤0.01% of the portfolio, ranked #3356.

UBS Group first reported a position in ACAD in Q4 2014 and has held it in 46 quarters since. The position peaked at $22.8M in Q4 2024. 341 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

UBS Group held 448,549 shares of Acadia Pharmaceuticals worth $9.98M as of Q1 2026.
UBS Group sold 320,843 Acadia Pharmaceuticals shares in Q1 2026, an estimated $7.67M.
Acadia Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3356 holding.
UBS Group first reported a position in Acadia Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
UBS Group's Acadia Pharmaceuticals position peaked at $22.8M in Q4 2024.
341 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.